Health stocks traded Tuesday on a variety of business and regulatory news. The Nasdaq and Amex biotechnology indices hopped 1.7% and 1.4%, respectively. They outdid the Amex pharmaceutical index, which registered a 0.8% rise, more in line with the broader markets. Bellwether Biogen Idec BIIB tacked on $3.41, or 6%, to $59.30, while fellow biotech Genentech DNA added $2.49, or 3.3%, to $78.39. A component of the Nasdaq biotech index, Myriad Genetics MYGN regained $5.87, or 12.9%, to $51.39 a day after the company said its experimental Alzheimer's treatment Flurizan failed a late-stage study and will no longer be developed More clinical news, Halozyme HALO said late Monday that based on results of an ongoing phase I/IIa study its Chemophase combination treatment was well-tolerated and appeared safe with no dose-limiting...
[read full story]
Your Web Site
